GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNF) » Definitions » YoY EBITDA Growth

Epigenomics AG (Epigenomics AG) YoY EBITDA Growth : -97.04% (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Epigenomics AG YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Epigenomics AG's YoY EBITDA Growth for the quarter that ended in Jun. 2023 was -97.04%.

Epigenomics AG's EBITDA per Share for the three months ended in Jun. 2023 was $-2.60.


Epigenomics AG YoY EBITDA Growth Historical Data

The historical data trend for Epigenomics AG's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG YoY EBITDA Growth Chart

Epigenomics AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.00 21.26 29.23 91.61 -273.68

Epigenomics AG Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.63 -141.22 -241.36 -55.59 -97.04

Epigenomics AG YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Epigenomics AG's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (A: Dec. 2022 )
=(EBITDA per Share (A: Dec. 2022 )-EBITDA per Share (A: Dec. 2021 ))/ | EBITDA per Share (A: Dec. 2021 ) |
=(-14.622--3.913)/ | -3.913 |
=-273.68 %

Epigenomics AG's YoY EBITDA Growth for the quarter that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (Q: Jun. 2023 )
=(EBITDA per Share (Q: Jun. 2023 )-EBITDA per Share (Q: Jun. 2022 )) / | EBITDA per Share (Q: Jun. 2022 )) |
=(-2.599--1.319)/ | -1.319 |
=-97.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Epigenomics AG YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (Epigenomics AG) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines